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Introduction {#sec1}
============

The angiopoietin (Ang)-Tie signaling pathway is an important signaling pathway involved in vascular development, angiogenesis, and remodeling, as well as in the regulation of vascular permeability, homeostasis, quiescence, and stability ([@bib3], [@bib13], [@bib22], [@bib61]). Over the past decade, the angiopoietin-Tie signaling pathway has been the subject of a tremendous amount of research in search of therapeutic opportunities for many diseases ([@bib53]). In the cardiovascular system, dysregulation in the angiopoietin-Tie signaling axis has been linked to vascular impairment, ischemia/reperfusion injury, development of atherosclerotic plaques, as well as peripheral arterial disease ([@bib19], [@bib20], [@bib63], [@bib67]). In ocular diseases including diabetic macular edema and wet age-related macular degeneration, angiopoietin-Tie signaling is crucial in regulating retinal and choroidal neovascularization and vascular leakage ([@bib29], [@bib57]). The role of Tie2 in cancer, as well as in inflammation, is also being actively explored ([@bib26], [@bib42], [@bib47]). Recently, angiopoietin-1 (Ang1) has also been studied as a neuroprotective agent that inhibits neural apoptosis ([@bib70]).

The angiopoietin family of proteins consists of Ang1, Ang2, Ang3, and Ang4 that bind to their receptor Tie2. Ang1 and Ang2 have been identified as the main ligands for Tie2 ([@bib12], [@bib37]). Ang3 and Ang4 are mouse and human orthologs that are less well studied with unclear biological functions ([@bib16], [@bib35]). Ang1, the natural agonist of Tie2, binds and activates Tie2 to promote vascular stability and is secreted by quiescent, mature vessels ([@bib62]). Ang2 has historically been considered an antagonist that competitively inhibits Ang1 binding and is usually secreted in diseased or remodeling vessels ([@bib37], [@bib62]). Recent discoveries that Ang2 can act as agonist under certain conditions suggest that Ang2\'s role is highly context dependent ([@bib30], [@bib62], [@bib72]). Native Ang1 exists in highly oligomerized forms, forming tetrameric or higher-order multimeric structures, whereas native Ang2 exists in lower oligomeric forms, forming mainly dimers, trimers, or tetramers ([@bib31]). Ligand binding and ligand-specific responses of Tie2, including its trafficking and activation, have been observed to be influenced by the ligand oligomerization state, with the tetrameric form being the lowest oligomeric form of ligand required for Tie2 activation ([@bib31], [@bib48]). Activation of Tie2 by either Ang1 or Ang2 results in receptor internalization and release of ligands ([@bib7]). Vascular endothelial protein tyrosine phosphatase (VE-PTP) regulates the activation of Tie2 by catalyzing its dephosphorylation ([@bib15]).

Tie1 has been historically considered an orphan receptor, with no identified natural ligand. A recent study has identified leukocyte cell-derived chemotaxin 2 as a functional ligand of Tie1, modulating its interaction with Tie2 ([@bib68]). The role of Tie1 in the regulation of the angiopoietin-Tie signaling axis is controversial and not completely understood. Korhonen et al. reported that Tie1 is required for the agonistic activity of Ang2 on Tie2 ([@bib33]). Seegar et al. proposed that Tie1 negatively regulates Tie2 activation by pre-forming heterodimers with Tie2 and that the functional difference between Ang1 and Ang2 can be explained by the ability of Ang1 to dissociate Tie2 from the Tie1-Tie2 dimer ([@bib56]). Recent studies by Savant et al. and La Porta et al. proposed that Tie1 can both reduce and sustain Tie2 activation depending on the subpopulation of the cell and time ([@bib34], [@bib55]). Both Tie1 and Tie2 extracellular domains are known to be cleaved from the cell surface constitutively and in response to certain growth factors and cytokines ([@bib18], [@bib39]). Tie1 has been shown to co-localize with Tie2 at cell-cell contacts ([@bib33], [@bib43]). The exact mechanisms of action of how Tie1 interacts with and affects Tie2 signaling remain elusive. The complex effects of Tie1 on the surface presentation of Tie2, the subcellular localization of Tie2, and downstream Tie2 signaling require understanding the signaling at a network level. Computational modeling allows us to test the effects of different perturbations *in silico* under different assumptions about the molecular mechanisms and motivates further experimental studies to elucidate the role of Tie1 and Tie2 in the entire network.

Because of the central role of Tie2 activation in promoting vascular stability, therapeutic drugs that target the angiopoietin-Tie signaling axis to enhance Tie2 activation have been extensively explored in ischemic vascular diseases, various types of cancer, ocular diseases, as well as in inflammation. Therapeutics targeting the angiopoietin-Tie signaling axis are reviewed in Saharinen et al. ([@bib53]). Clinical development of angiopoietin-Tie-targeting therapeutics has been met with many obstacles, partly due to the complexity and limited understanding of this signaling pathway. Development of MEDI3617, a selective Ang2 antibody, was halted at phase I because of limited clinical activity ([@bib27]). Nesvacumab, an Ang2-targeting antibody, was stopped at phase II after failing to provide enough evidence to warrant phase III study ([@bib46]). Therapies targeting the angiopoietin-Tie2 pathway that are currently in clinical development include AKB-9778, a small molecule inhibitor of VE-PTP ([@bib8], [@bib57]); trebananib, a peptibody that inhibits the binding of both Ang1 and Ang2 to Tie2 ([@bib64]); vanucizumab, a bispecific antibody against both vascular endothelial growth factor (VEGF) and Ang2 ([@bib25]); and faricimab, a bispecific antibody that shares the same targets (VEGF and Ang2) ([@bib54]). Therapies targeting the angiopoietin-Tie pathway in preclinical development include cartilage oligomeric matrix protein-Ang1 ([@bib9], [@bib50]), an Ang1 variant that has stronger agonistic activity than native Ang1; Ang2-binding Tie2-activating antibody ([@bib23]), which converts Ang2 to a Tie2 agonist; VA1 ([@bib2]), a VEGF- and Ang1-mimetic that binds and activates both VEGF receptor VEGFR2 and Tie2; and AXT107, a small peptide that enhances Tie2 activation and works by modulating the integrin/Tie2 interaction ([@bib43]). There remains a need to discover and to quantitatively understand the molecular strategies targeting the angiopoietin-Tie axis that promote Tie2 activation and enhance the vascular protective function of endothelial cells in the disease settings. The present study uses a computational model to study the network of signaling events in the angiopoietin-Tie signaling axis and to quantitatively characterize the effects of different perturbations on the system and their potential synergism or antagonism.

Computational modeling of vascular signaling allows the complex integration of signaling pathways, their regulatory mechanisms, and crosstalk to quantitatively investigate the intricate interplays of molecular mechanisms and effects of perturbations in the signaling pathways involved in angiogenesis and vascular leakage. Previously, we have used computational modeling to study other major vascular signaling pathways, namely the VEGF signaling pathway and the hepatocyte growth factor (HGF) signaling pathway, along with their downstream signaling, regulation, and crosstalk with integrins ([@bib4], [@bib5], [@bib28]). These computational studies have helped us quantitatively predict and understand the molecular mechanisms of how perturbations in these signaling pathways potentially affect the signaling outcomes. This study aims to use a similar approach to gain a quantitative understanding of various molecular aspects of the angiopoietin-Tie signaling pathway on a network level.

The present study uses a computational signaling pathway model validated against experimental data to quantitatively study various mechanistic aspects of the angiopoietin-Tie signaling pathway, including receptor activation, trafficking, turnover, and molecular mechanisms of its regulation. The calibrated model captures and reproduces experimental results reported from independent sources and provides mechanistic insights into the controversial roles of Ang2 and its regulators VE-PTP and Tie1. The model quantitatively predicts the synergistic effects of inhibition of VE-PTP, Tie1, and Tie2 cleavage on enhancing vascular protective actions of Tie2.

Results {#sec2}
=======

A Computational Model Calibrated to Experimental Data Captures and Reproduces Experimental Results {#sec2.1}
--------------------------------------------------------------------------------------------------

The computational model of the angiopoietin-Tie signaling pathway in the present study includes detailed mass actions of the molecular mechanisms for the ligand and receptor interactions (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The reaction rules are summarized in [Figure 1](#fig1){ref-type="fig"}.Figure 1Diagram of Model Reaction RulesAng1 (tetrameric) and Ang2 (dimeric, trimeric, and tetrameric) induce oligomerization, phosphorylation, and internalization of Tie2. Orphan receptor Tie1 binds and forms heterodimers with receptor Tie2. Internalized receptors are recycled back to the cell surface or degraded. Receptors Tie1 and Tie2 get cleaved from the surface and form soluble receptors Tie1 and Tie2. Soluble Tie2 binds to both ligands Ang1 and Ang2. See also [Table S2](#mmc1){ref-type="supplementary-material"}.

Ang1 is assumed to be in tetrameric form, whereas Ang2 varies between dimeric, trimeric, and tetrameric forms. The model further assumes that the oligomerized ligands, after binding to the receptor, induce fast oligomerization of the receptors. Tetramerized Tie2 receptors bound to either Ang1 or Ang2 can auto-phosphorylate and activate. On the cell surface, VE-PTP is assumed to catalyze dephosphorylation with Michaelis-Menten kinetics, where VE-PTP binds to and dissociates from phosphorylated Tie2 at constant rates, and once associated with Tie2, VE-PTP catalyzes the dephosphorylation reaction at a constant rate. Upon activation, the receptors are internalized, and the ligands are released back to the surface of the cell. Receptor Tie1 is assumed to not be able to bind to any ligand but can heterodimerize with receptor Tie2. Tie1-Tie2 heterodimers can bind to both Ang1 and Ang2, and Ang1 can induce the dissociation of Tie2 from the Tie1-Tie2 heterodimers. Furthermore, both receptors Tie1 and Tie2 are constitutively shed from the surface, turning into soluble Tie1 and soluble Tie2, respectively. Soluble Tie2 can bind to ligands and oligomerize in the extracellular space but is unable to phosphorylate or internalize. Internalized receptors and soluble receptors are degraded by first-order elimination.

The calibrated model was able to capture and reproduce experimental results reported from independent sources. Consistent with the studies by Bogdanovic et al. and Yuan et al., the model shows that in endothelial cells, both ligands Ang1 and Ang2 activate receptor Tie2 in a ligand-dependent manner, with Ang2 being a weaker agonist than Ang1 ([@bib7], [@bib72]) ([Figures 2](#fig2){ref-type="fig"}A--2D). In addition, the model also captures the different receptor internalization rates when induced by Ang1 and Ang2, which affect the overall degradation of Tie2 ([@bib7]) ([Figures 2](#fig2){ref-type="fig"}E and 2F). Furthermore, the model is able to capture that silencing receptor Tie1 enhances both Ang1- and Ang2-induced Tie2 activation at 15 min following angiopoietin treatment in endothelial cells as reported in the study by Seegar et al. ([Figures 2](#fig2){ref-type="fig"}G and 2H) ([@bib56]). Consistent with experiments by Findley et al. and Marron et al., the model reproduces the constitutive extracellular domain shedding of receptors Tie2 and Tie1 from the cell surface, producing soluble receptors in the extracellular space ([Figures 2](#fig2){ref-type="fig"}I and 2J) ([@bib18], [@bib39]). Finally, the calibrated model reproduces the concentration-dependent inhibition effect of soluble Tie2 treatment on Tie2 activation by acting as a ligand trap as reported in Alawo et al. ([Figure 2](#fig2){ref-type="fig"}K) ([@bib1]). The parameters, observables, reactions, and the data used in the calibration are tabulated in [Tables S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc1){ref-type="supplementary-material"}, [S3](#mmc3){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}.Figure 2Model Calibration Using Global Optimization(A and B) The concentration-dependent agonistic activity of (A) Ang1 and (B) Ang2.(C and D) Ang2 functions as partial agonist compared to Ang1.(E and F) Ang1 and Ang2 induce different receptor trafficking and turnover of Tie2.(G and H) Silencing orphan receptor Tie1 enhances Ang1- and Ang2-induced Tie2 activation.(I and J) Receptors Tie2 and Tie1 are constitutively shed from the cell surface and produce soluble receptors.(K) Soluble Tie2 induces concentration-dependent inhibition of Tie2 activation. Where available, data are presented as mean +/− standard error of the mean (SEM).See also [Table S4](#mmc1){ref-type="supplementary-material"}.

The uncertainty of parameter estimations using global optimization due to measurement errors in the dataset was assessed using the bootstrap method ([@bib14], [@bib60]). The distributions of optimal parameters obtained using 50 re-sampled datasets are visualized in the violin plot in [Figure S1](#mmc1){ref-type="supplementary-material"}A. Local sensitivity analysis was performed on all optimal parameter sets obtained using re-sampled datasets to assess the identifiability of the parameters. We assumed that a parameter is identifiable if 95% of the local sensitivity distribution maintains a consistent sign, as in previous studies ([@bib60]). Of all fitted parameters, the internalization rates of phosphorylated Tie2 (kintang1ptie, kintang2ptie) and the degradation rates of soluble receptors (kdegstie1, kdegstie2) were unidentifiable ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

VE-PTP Dephosphorylates Ang2-Activated Tie2 More Effectively Than Ang1-Activated Tie2 {#sec2.2}
-------------------------------------------------------------------------------------

Ang2 acts as a Tie2 agonist in lymphatic endothelial cells, whereas in blood endothelial cells, Ang2 acts mostly as an antagonist. A recent study by Souma et al. proposed that VE-PTP controls the context-dependent function of Ang2 by differentially regulating Ang1- and Ang2-activated Tie2 ([@bib59]) ([Figure 3](#fig3){ref-type="fig"}A). Souma et al. demonstrated in Tie2- and VE-PTP-transfected cells that VE-PTP can abolish Ang2-induced Tie2 activation but is less effective in dephosphorylating Ang1-induced phosphorylated Tie2. The model did not assume different reactions or reaction rates for the dephosphorylation of Ang1- or Ang2-activated Tie2 by VE-PTP and was not calibrated to these data. Simulations of knocking down VE-PTP predicted that adding VE-PTP to Ang2-activated Tie2 reduced Tie2 phosphorylation by 90% but has little to no effect on Ang1-activated Tie2 ([Figures 3](#fig3){ref-type="fig"}B and 3C), consistent with the data reported by Souma et al.Figure 3VE-PTP Reduces Ang2-Induced Activation of Tie2, but Not Ang1(A) VE-PTP is more effective in regulating Ang2-activated Tie2 compared to Ang1-activated Tie2.(B) Simulation of concentration-dependent activation of Tie2 with VE-PTP by Ang1 and concentration-dependent activation of Tie2 without VE-PTP by Ang1 compared to experimental data by Souma et al.(C) Simulation of concentration-dependent activation of Tie2 with VE-PTP by Ang2 and concentration-dependent activation of Tie2 without VE-PTP by Ang2 compared to experimental data by Souma et al. Data are presented as mean ± SEM.

Simulations were then performed to investigate the molecular mechanisms of how VE-PTP differentially regulates Ang1- and Ang2-activated Tie2. We hypothesize that the internalization rates of Ang1- and Ang2-activated Tie2 modulate the responsiveness of Tie2 activation to VE-PTP dephosphorylation ([Figure 4](#fig4){ref-type="fig"}A). To understand how internalization rates affect the action of VE-PTP, the internalization rate of Ang1-bound Tie2 was varied from its baseline value to one-hundredth of the baseline value to investigate the effect of internalization rate on the effectiveness of VE-PTP. At baseline value for Ang1-activated Tie2 (fast internalization), VE-PTP has little effect on phosphorylated Tie2 when VE-PTP is added ([Figure 4](#fig4){ref-type="fig"}B). When the internalization rate is decreased to one-hundredth of its baseline value, VE-PTP reduces phosphorylated Tie2 by 80% ([Figure 4](#fig4){ref-type="fig"}C). The ratio of phosphorylated Tie2 at 30 min in the presence of VE-PTP and absence of VE-PTP increases as the internalization rate of Ang1-bound Tie2 increases from one-hundredth of its baseline value to the baseline value ([Figure 4](#fig4){ref-type="fig"}D). In Ang2-treated cells, the ratio of phosphorylated Tie2 in the presence of VE-PTP and absence of Tie2 also increases as the internalization rate of Ang2-bound Tie2 increases. At the baseline internalization rate, VE-PTP reduces phosphorylated Tie2 by 80% ([Figure 4](#fig4){ref-type="fig"}E). Increasing the internalization rate by 100-fold decreases the effectiveness of VE-PTP ([Figure 4](#fig4){ref-type="fig"}F). The ratio of phosphorylated Tie2 at 30 min in the presence of VE-PTP and absence of VE-PTP also increases as the internalization rate of Ang2-bound Tie2 increases from its baseline value to 100 times the baseline value ([Figure 4](#fig4){ref-type="fig"}G).Figure 4Effect of Internalization Rate on the Effectiveness of VE-PTP(A) Ang1 induces faster internalization of Tie2 compared to Ang2.(B and C) Simulation of phosphorylated Tie2 over time following Ang1 treatment with and without VE-PTP at (B) baseline internalization rate and (C) reduced internalization rate.(D) The ratio of phosphorylated Tie2 at 30 min with and without VE-PTP increases as internalization rate increases following Ang1 treatment.(E and F) Simulation of phosphorylated Tie2 over time following Ang1 treatment with and without VE-PTP at (E) baseline internalization rate and (F) increased internalization rate.(G) The ratio of phosphorylated Tie2 at 30 min with and without VE-PTP increases as internalization rate increases following Ang2 treatment.

Tie2 Phosphorylation Is Sensitive to Parameters for Tie2 Cleavage, VE-PTP Action, and Tie1 Expression {#sec2.3}
-----------------------------------------------------------------------------------------------------

We performed global sensitivity analysis using Latin hypercube sampling and partial rank correlation coefficient (PRCC) ([@bib38]) to look at the effect of changes in parameters on some outputs of the model, most importantly, on the activation of Tie2 (phosphorylated Tie2 at 30 min) and trafficking of Tie2 (internalized Tie2 at 30 min). Statistically significant parameters (Bonferroni corrected p value \< 0.01) with positive and negative PRCC values (from high to low) for internalized Tie2 and phosphorylated Tie2 are shown in [Figures 5](#fig5){ref-type="fig"}A and 5B. The PRCC values for all parameters and more outputs from the model are shown in [Figure 5](#fig5){ref-type="fig"}C. A table with all parameters, their names, and description, along with their best-fit values are included in the Supplementary Data file ([Table S1](#mmc1){ref-type="supplementary-material"}).Figure 5Global Parameter Sensitivity Analysis(A) Sensitive parameters for internalized Tie2 at 30 min post-stimulation and their partial rank correlation coefficient (PRCC) values.(B) Sensitive parameters for phosphorylated Tie2 at 30 min post-stimulation and their PRCC values.(C) PRCC values for all parameters on the observables of the model. Tables with all parameters ([Table S1](#mmc1){ref-type="supplementary-material"}) and all observables ([Table S3](#mmc3){ref-type="supplementary-material"}) are included in the [Supplemental Information](#mmc1){ref-type="supplementary-material"}.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Internalized Tie2 at 30 min is sensitive to the initial concentration of Tie2 (Tie2_0) and the synthesis rate of Tie2 (ksyntie2). Internalized Tie2 concentration is especially sensitive to parameters involved in the trafficking and turnover of Tie2 (krectie2, kdegptie2), as well as to the initial concentrations of the ligands (Ang1_4\_0, Ang2_2\_0, and Ang2_4\_0), and the dissociation rate constant of Ang2 (kD_ang2) ([Figure 5](#fig5){ref-type="fig"}A). Phosphorylated Tie2 at 30 min is sensitive to the initial phosphorylation rate (kpang1tie2), initial concentration of Tie2 (Tie2_0), and trafficking parameters, including the internalization rate of phosphorylated Tie2 (kintang1dptie2, kintang2dptie2), recycling rate (krectie2), and degradation rate of phosphorylated Tie2 (kdegptie2). Initial concentrations of tetrameric ligands (Ang1_4\_0, Ang2_4\_0) have a positive correlation with Tie2 activation while the initial concentration of ligands in lower oligomeric forms (Ang2_2\_0) has a negative PRCC value ([Figure 5](#fig5){ref-type="fig"}B).

Noticeably, Tie2 activation is found to be sensitive to parameters for various regulation mechanisms in the angiopoietin-Tie signaling axis, including VE-PTP and Tie1 and Tie2 cleavage. Phosphorylated Tie2 is sensitive to parameters for VE-PTP action, including the initial concentration of VE-PTP (VEPTP_0) and the binding rate of VE-PTP to activated Tie2 (konveptp), with both of them having negative PRCC values. The dissociation rate of VE-PTP binding has a negative PRCC value, suggesting inhibiting VE-PTP enhances Tie2 activation. Tie2 activation is also sensitive to Tie1-related parameters. The synthesis rate of Tie1 (ksyntie1), initial concentration of Tie1 (Tie1_0), and association rate of Tie1:Tie2 binding (kontie1tie2) have negative PRCC values, whereas the cleavage rate of Tie1 (kcleavetie1), dissociation rate of Tie1:Tie2 heterodimer (kofftie1tie2), as well as the Ang1-induced dissociation rate of Tie1:Tie2 (kdissang1tie1tie2) have positive PRCC values with phosphorylated Tie2, suggesting that heterodimer formation with Tie1 inhibits Tie2 activation. Finally, phosphorylated Tie2 at 30 min is also sensitive to Tie2 cleavage rate (kcleavtie2), suggesting that cleavage of Tie2 inhibits Tie2 activation ([Figure 5](#fig5){ref-type="fig"}B).

Inhibition of Tie2 Cleavage, Inhibition of VE-PTP, and Silencing of Tie1 Enhance Activation of Tie2 {#sec2.4}
---------------------------------------------------------------------------------------------------

The global sensitivity analysis allows us to find potential perturbations of the system that enhance the activation of Tie2. The global sensitivity analysis suggested the potential Tie2 activation-enhancing effects of inhibition of Tie2 cleavage and concentration of VE-PTP and Tie1 ([Figure 6](#fig6){ref-type="fig"}A). The model is used to quantitatively study the effect of these perturbations and their synergistic effects on the enhancement of Tie2 phosphorylation.Figure 6Inhibition of Tie2 Shedding, VE-PTP, and Tie1 Rescues Ang2-Induced Tie2 Activation(A) Diagram of regulation mechanisms of Tie2 signaling: Tie2 shedding, VE-PTP action, and Tie1 binding.(B) Effect of inhibition of VE-PTP, Tie1, and Tie2 cleavage on maximum phosphorylated Tie2 for 30 min post-stimulation.(C) Effect of combination of inhibition of VE-PTP and Tie2 cleavage on maximum phosphorylated Tie2 for 30 min post-stimulation.(D) Effect of combination of inhibition of VE-PTP and Tie1 on maximum phosphorylated Tie2 for 30 min post-stimulation.(E) Effect of combination of inhibition of Tie1 and Tie2 cleavage on maximum phosphorylated Tie2 for 30 min post-stimulation.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Assuming a baseline simulation of Tie2 activation by 200 ng/mL of Ang2, the model predicts that the inhibition of Tie2 cleavage enhances maximal Tie2 phosphorylation by up to 1.34-fold, where complete inhibition of VE-PTP enhances maximal Tie2 phosphorylation by up to 5.5-fold, and Tie1 silencing enhanced Tie2 phosphorylation by up to 4.5-fold ([Figure 6](#fig6){ref-type="fig"}B). The combination of the different inhibition mechanisms demonstrated synergy in promoting activation of Tie2 ([Figures 6](#fig6){ref-type="fig"}C--6E). Combination of VE-PTP inhibition and inhibition of Tie2 cleavage enhances maximal Tie2 phosphorylation by Ang2 by up to 7.4-fold ([Figure 6](#fig6){ref-type="fig"}C). Although Tie1 silencing by itself has a moderate effect on enhancing Tie2 activation, Tie1 silencing significantly potentiates the responsiveness of Tie2 activation to both the inhibition of Tie2 cleavage and the inhibition of VE-PTP. With complete inhibition of Tie1, VE-PTP inhibition increases Tie2 phosphorylation by up to 25-fold ([Figure 6](#fig6){ref-type="fig"}D), and inhibition of Tie2 shedding increases Tie2 phosphorylation by 75-fold ([Figure 6](#fig6){ref-type="fig"}E). This further suggests the important role of the orphan receptor Tie1 in regulating Tie2 activation and its responsiveness to other regulatory mechanisms in the angiopoietin-Tie signaling axis.

Effect of inhibition of VE-PTP, Tie1 concentration, and Tie2 cleavage on Ang1-treated Tie2 is presented in [Figure S2](#mmc1){ref-type="supplementary-material"}. Inhibition of VE-PTP has little effect on enhancing Ang1-treated Tie2 activation because VE-PTP is less effective in regulating Ang1-activated Tie2. Combinations of VE-PTP inhibition with Tie1 silencing and with Tie2 cleavage inhibition are dominated by the effect of Tie1 silencing and Tie2 cleavage inhibition, respectively ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Combination of inhibition of Tie1 and Tie2 cleavage demonstrated synergy in enhancing Ang1-treated Tie2 activation ([Figure S2](#mmc1){ref-type="supplementary-material"}E).

The Model Captures and Reproduces the Dissociation of Tie1:Tie2 Heterodimer by Ang1 {#sec2.5}
-----------------------------------------------------------------------------------

To obtain a quantitative understanding of the molecular mechanism behind the inhibitory effect of Tie1, we compared our model prediction of dissociation of Tie1:Tie2 heterodimers with experimental data. Seegar et al. reported that Ang1, but not Ang2, induces the dissociation of Tie2 from Tie1:Tie2 heterodimer ([Figure 7](#fig7){ref-type="fig"}A) ([@bib56]). The model is able to capture and reproduce the dissociation of the heterodimer by Ang1 ([Figure 7](#fig7){ref-type="fig"}B). The model assumes that Ang1-bound heterodimers dissociate at a rate characterized by parameter kdissang1tie1tie2. This parameter was varied by 100-fold below or above its baseline value to understand the effect of changing the dissociation rate of Ang1-bound heterodimer on the concentration of heterodimer at 30 min. The dissociation rate does not affect Ang2-treated heterodimer. Heterodimer concentration at 30 min decreases as the dissociation rate increases for Ang1-treated endothelial cells ([Figure 7](#fig7){ref-type="fig"}C). The model also predicts that in addition to modulating ligand responsiveness, Tie1 is also predicted to modulate the responsiveness of Tie2 to other regulatory mechanisms including VE-PTP and Tie2 shedding ([Figures 6](#fig6){ref-type="fig"}D and 6E).Figure 7Ang1 Dissociates Tie2 from Tie1:Tie2 Heterodimer(A) Ang1, but not Ang2, stimulates dissociation of Tie1:Tie2 heterodimer.(B) The concentration of Tie1:Tie2 heterodimer over time following Ang2 treatment and Ang1 treatment compared to experimental results by Seegar et al.(C) Heterodimer concentration at 30 min decreases as kdissang1tie1tie2 increases following Ang1 treatment but does not change following Ang2 treatment. Data are presented as mean ± SEM.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Tie2 Activation Is Enhanced by Tie1 Cleavage and Regulated by Tie2 Cleavage {#sec2.6}
---------------------------------------------------------------------------

To understand the effect of extracellular domain cleavage of Tie1 and Tie2 on Tie2 signaling, the cleavage rates of Tie1 (kcleavagetie1) and Tie2 (kcleavagetie2) were varied 100-fold below or above their baseline values. Phosphorylated Tie2 at 30 min decreases as the Tie2 cleavage rate increases and increases as the Tie1 cleavage rate increases, suggesting that the molecular balance between surface Tie1 and Tie2 controls the activity of Tie2 ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Increasing the Tie2 cleavage rate by 100-fold diminishes phosphorylated Tie2 by more than 99%, whereas decreasing it by 100-fold increases phosphorylated Tie2 by 20% ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Increasing the Tie1 cleavage rate by 100-fold, on the other hand, enhances phosphorylated Tie2 by up to 6 times ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

Discussion {#sec3}
==========

The angiopoietin-Tie signaling axis is tightly regulated by the complex interplay of molecular balance between the ligands, receptor availability, trafficking, degradation, and various regulatory mechanisms including VE-PTP binding, Tie1 binding, and receptor ectodomain cleavage. The computational model calibrated against experimental data provides a platform for quantitative investigation of these regulation mechanisms, and the effects of perturbations or therapeutics targeting these mechanisms. The model also suggests further experiments to build a better understanding of the complex signaling events in the angiopoietin-Tie signaling axis.

Receptor Trafficking Kinetics Affects VE-PTP Efficacy, Causing It to Differentially Regulate Ang1- and Ang2-Activated Tie2 {#sec3.1}
--------------------------------------------------------------------------------------------------------------------------

The activity of VE-PTP regulates the phosphorylation of Tie2 and its downstream signaling. Ang2 functions as an agonist in lymphatic endothelial cells in the absence of VE-PTP and as an antagonist in blood endothelial cells in the presence of VE-PTP. Souma et al. suggested that VE-PTP plays a role in determining the context-dependent function of Ang2 by abrogating Ang2-activated Tie2 in blood endothelial cells ([@bib59]). Inhibiting VE-PTP would, therefore, convert Ang2 to an agonist, stabilizing the vasculature through activation of Tie2 ([@bib57]).

The mechanism of how VE-PTP differentially regulates Ang1- and Ang2-activated Tie2 is not clear. VE-PTP regulates Tie2 by directly associating with Tie2 and catalyzing its dephosphorylation ([@bib66]). Ang1 and Ang2 share the same binding domains and have similar kinetics of binding to Tie2 ([@bib12], [@bib17], [@bib37]). The major differences between the two ligands are their oligomerization states and the receptor internalization kinetics that they induce. Ang1 induces higher internalization rates of Tie2 compared to Ang2 ([@bib7]). Our simulation indeed demonstrated the role of internalization rates in modulating the efficacy of VE-PTP by showing that decreasing the internalization rate of Ang1-activated Tie2 increases the VE-PTP efficacy and that increasing the internalization rate of Ang2-activated Tie2 has the reverse effect ([Figure 4](#fig4){ref-type="fig"}). Based on these results, we propose that the different trafficking kinetics induced by Ang1 and Ang2 can explain the difference in VE-PTP efficacy. We hypothesize that experiments simultaneously examining the internalization of Tie2 and effect of VE-PTP would help further elucidate the molecular mechanism of VE-PTP\'s action and that therapeutically increasing the internalization rate of Ang2-activated Tie2 may enhance the agonistic function of Ang2.

The Orphan Receptor Tie1 Regulates Tie2 Responsiveness and Ligand Activity by Forming Heterodimers That Can Dissociate When Bound to Ang1 {#sec3.2}
-----------------------------------------------------------------------------------------------------------------------------------------

Tie1 is an orphan receptor with no identified ligand ([@bib33], [@bib34], [@bib45], [@bib55], [@bib56], [@bib67]). Tie1 interacts with the angiopoietin-Tie signaling axis by forming a heterodimer with Tie2 ([@bib36]). The role of Tie1 in regulating Tie2 signaling is contradictory. Some studies suggested that Tie1 is required for the agonistic activity of the angiopoietins ([@bib11], [@bib33]), whereas others have suggested that Tie1 acts as an inhibitor of Tie2 activation ([@bib39], [@bib56], [@bib71]). Savant et al. proposed that Tie1 exerts context-dependent functions according to endothelial cell subpopulations: in tip cells, Tie1 counter-regulates Tie2 by limiting its surface presentations, whereas, in stalk cells, Tie1 sustains Tie2 by co-localizing with Tie2 ([@bib55]). A subsequent study by La Porta et al. further reported the effect of Tie1 deletion on vessel stabilization through angiopoietin-Tie signaling ([@bib34]). The Tie2-sustaining and angiopoietin-potentiating role of Tie1 can be partly explained by its co-localization with Tie2 at cell junctions ([@bib36]). Savant et al. have also suggested that Tie1:Tie2 heterodimers co-localize at cell-cell contacts, thereby serving as a reservoir for sustained Tie2 signaling ([@bib55]), in agreement with previous studies ([@bib24], [@bib51]). The present model, without considering the junctional localization of the receptors, more closely models the tip cell population discussed in Savant et al., and therefore, focuses on investigating the molecular mechanisms of Tie1 as an inhibitor of Tie2. We acknowledge that the molecular mechanisms of the Tie2-enhancing activity of Tie1 need to be further investigated in subsequent studies where junctional localization is considered.

The model assumes that Tie1 forms heterodimers with Tie2, limiting access of Tie2 to the ligands and effectively inhibiting Tie2 activation. This effect of Tie1 is consistent with and calibrated to the study reported by Seegar et al. ([@bib56]). In their study, Seegar et al. showed using a fluorescence resonance energy transfer assay that Tie1 and Tie2 can pre-form heterodimers in the absence of ligand, and Ang1 is able to dissociate Tie2 from heterodimers upon binding, distinguishing it from Ang2, which cannot induce dissociation of the heterodimer ([Figure 7](#fig7){ref-type="fig"}). Korhonen et al., on the other hand, showed that the interaction of Tie1 and Tie2 increased after ligand stimulation and that Tie1:Tie2 heterodimers are observed at cell-cell contacts ([@bib33]). The enhancement of heterodimer formation induced by ligand potentially contributes to the Tie2-sustaining function of Tie1. The model, without implementing junctional localization, is not yet able to reproduce this phenomenon at its current stage. In both cases, Tie1 receptors play an important role in the regulation of Tie2 activation by Ang2. Indeed, Song et al. reported that compared to blood endothelial cells, lymphatic endothelial cells have a reduced level of expression of Tie1, suggesting that the limited regulation by Tie1 might be another factor contributing to the agonistic activity of Ang2 in lymphatic endothelial cells in addition to the lack of VE-PTP expression there ([@bib58]). In addition, Tie1 has been demonstrated to affect the localization and, therefore, the internalization rate of Tie2 ([@bib33], [@bib55], [@bib56]). Our model predicts that the internalization rate of Tie2 modulates the responsiveness of Tie2 to regulation by VE-PTP ([Figure 4](#fig4){ref-type="fig"}), further complicating the regulation of Tie2 activation by Ang2. Our hypothesis that the context-dependent function of Ang2 in blood endothelial cells and in lymphatic endothelial cells is controlled jointly by VE-PTP and Tie1 can be readily tested by further experiments in both cell types.

Extracellular Domain Cleavage of Tie1 and Tie2 Modulates Angiopoietin-Tie Signaling {#sec3.3}
-----------------------------------------------------------------------------------

Cleavage of Tie2 from the cell surface is an important regulatory mechanism in the angiopoietin-Tie signaling pathway ([@bib49]). In addition to limiting the availability of receptors, the product of the extracellular domain shedding, soluble Tie2, also acts as a ligand trap by binding to the ligands in the extracellular space ([@bib1]). Soluble Tie2 is found to be elevated in many microvasculature-related diseases, including inflammation ([@bib47]), systemic sclerosis ([@bib44]), congestive heart failure ([@bib10]), and peripheral arterial disease ([@bib19]). In pathological angiogenesis, Tie2 signaling is not only attenuated by the antagonistic activity of Ang2, but VEGF also induces extracellular domain cleavage of Tie2 in a phosphoinositide-3 kinase/Akt-dependent manner, further diminishing the activity of Tie2 ([@bib18]). *In vitro*, soluble Tie2 represses Tie2 signaling in a concentration-dependent manner ([@bib1]), consistent with the clinical observation that, among patients with peripheral arterial disease, the plasma level of soluble Tie2 distinguishes patients with intermittent claudication and those with critical limb ischemia, the more severe manifestation ([@bib19]). In accordance with experimental findings, the model predicts the concentration-dependent inhibition of Tie2 activation by soluble Tie2 ([Figure 2](#fig2){ref-type="fig"}K) and the inhibitory effect of increasing the extracellular domain shedding rate of Tie2 ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

The orphan receptor Tie1 also undergoes extracellular domain cleavage. This process has been observed to be mediated by protein kinase C and metalloproteases ([@bib41], [@bib69]). Phorbol ester and VEGF also stimulate extracellular domain cleavage of Tie1 ([@bib39]). Marron et al. further proposed that the proteolytic cleavage of Tie1 serves the role of modulating ligand responsiveness of Tie2 ([@bib39]). Model simulations have indeed shown that Tie2 activation can be enhanced by increasing the extracellular domain shedding rate of Tie1 ([Figure S3](#mmc1){ref-type="supplementary-material"}A) and that Tie1 silencing can modulate Tie2 responsiveness to other regulatory mechanisms such as VE-PTP inhibition and inhibition of Tie2 cleavage ([Figures 6](#fig6){ref-type="fig"}D and 6E).

In conclusion, the present study uses a computational model of the angiopoietin-Tie signaling pathway to investigate the major aspects of the molecular mechanisms of Tie2 signaling and its regulation in endothelial cells. The calibrated model captured and explained multiple experimental observations of the Tie2 signaling pathway, including the action of regulator VE-PTP and the controversial role of Tie1 and Ang2. The model predicted the synergistic effects of inhibition of VE-PTP, Tie1, and Tie2 cleavage on enhancing the vascular protective actions of Tie2. Simulations showed the role of internalization rate in determining the differential efficacy of VE-PTP in regulating Ang1- and Ang2-activated Tie2 and explored the role of extracellular domain shedding of Tie1 and Tie2 in Tie2 activation. In addition, the model suggested the role of Tie1 silencing in the responsiveness of Tie2 to VE-PTP inhibition and inhibition of Tie2 cleavage. The model also motivates further experimental studies to investigate the molecular mechanisms of VE-PTP and Tie1 and to validate the potential synergism predicted by the model.

Overall, the present computational model of the angiopoietin-Tie pathway allows us to make perturbations on many isolated aspects of the molecular mechanisms in the complex reaction network formed by the singling pathway and to quantitatively study the effects of these perturbations that would be otherwise difficult to achieve experimentally. The model serves to further our understanding of the angiopoietin-Tie2 pathway, suggests additional experiments that can further elucidate the molecular mechanisms, and provides a platform for testing and quantitatively studying the signaling pathway, therapeutics targeting the pathway, and crosstalk with other cellular signaling pathways at a molecular level.

Limitations of the Study {#sec3.4}
------------------------

An important limitation of the model is that it does not take into account the subcellular localization of the Tie2 receptors to cell-cell junctions and cell-matrix contacts, as observed in confluent endothelial cells. Tie2 receptors at cell-ECM contacts and at cell-cell junctions have different effects on downstream signaling through extracellular signal-regulated kinases (ERK), Akt/endothelial nitric oxide synthase (eNOS), and Dok-R pathways ([@bib21], [@bib52]). Tie1 and integrins can also affect Tie2 signaling by affecting the localization and internalization of Tie2 ([@bib33], [@bib43], [@bib55], [@bib56]).

In addition, the role of Tie1 in Tie2 activation and its exact molecular mechanisms of action remain controversial. The present model mostly considers the function of Tie1 as a regulator of the surface presentation of Tie2. This inhibitory role of Tie1 has been observed in a number of previous studies ([@bib24], [@bib39], [@bib55], [@bib56]), whereas the Tie2-enhancing activities of Tie1 have also been observed ([@bib32], [@bib33], [@bib45], [@bib55]). Studies have also suggested a potential dual function of Tie1 where it regulates the presentation of Tie2 at the cell surface but sustains Tie2 signaling by co-localizing with it at cell-cell junction ([@bib34], [@bib55]). We acknowledge that the results of the model are based on the assumption of Tie1 as an inhibitor of Tie2 and that the present model cannot fully recapitulate the experimental findings on the role of Tie1 because of lack of sufficient experimental data on the junctional localization of Tie2. Future studies should consider the molecular mechanisms by which Tie1 enhances and sustains Tie2 signaling when such experimental data are available. The current model also motivates additional experimental studies into the molecular mechanisms of Tie1 to further elucidate its role.

The present model also does not consider the signaling of receptors and action of VE-PTP in endosomal compartments, which has been observed in many receptor tyrosine kinases, because of limitation of experimental data ([@bib65]). Additionally, the downstream signaling of Tie2 is not considered. Tie2 signaling shares many downstream signaling features with other signaling pathways, including the VEGF signaling pathway through Akt/eNOS ([@bib4]), and the HGF/Met signaling pathway through Akt ([@bib28]). VEGF also affects Tie2 signaling by inducing the release of Ang2 stored in Weibel-Palade bodies ([@bib40]) and stimulating the extracellular domain cleavage of Tie2 ([@bib18]). A recent study demonstrated that targeting microRNA-15a and microRNA-16 enhanced Tie2 signaling and improved angiogenesis and perfusion ([@bib6]), suggesting that the present model can further integrate with computational models of microRNAs to elucidate the intricate interplay between microRNAs, VEGF pathway, and angiopoietin-Tie pathway ([@bib73], [@bib74]). The current model provides a platform for further analysis of Tie2 localization and crosstalk with integrin and other signaling pathways to be explored in subsequent studies.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The model reaction network, as an SBML file, is available in the Supplemental Files ([Data S1](#mmc2){ref-type="supplementary-material"}). All parameter values, datasets, and reactions used in the model are included in the [Supplemental Information](#mmc1){ref-type="supplementary-material"}.
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